Peer-Reviewed Publication
J Clin Oncol2026;44(14):1283-1295.May 10, 2026Journal Article
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
Natasha B Hunter1, Heather A Parsons1,2, Leslie Cope3, Jenna V Canzoniero3, Fabio C P Navarro4, Sherif El-Refai4, Jesus D Anampa5, Joseph A Sparano5, Mothaffar Rimawi6, Anna Maria Storniolo7, Candace Mainor8, Rita Nanda9, Angela DeMichele10, Gaorav P Gupta11, Erica J Stringer-Reasor12, Filipa Lynce2,8, Erin F Cobain13, Shannon Puhalla14, Rachel Jankowitz10,14, Brent Rexer15, Ingrid Mayer15, E Shelley Hwang16, Kimberly Blackwell16, Walid El Ayass17, Young Lee18, Carol Tweed18, Mary Wilkinson3,19, Angela Pennisi19, Bonnie Sun3, Pamela Wright3, Julie R Gralow1, Richard Chen4, Sean M Boyle4, Vered Stearns3, Antonio C Wolff3, Ben Ho Park15
1Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.
2Dana Farber Cancer Institute, Boston, MA.
3Johns Hopkins University, Baltimore, MD.
4Personalis, Fremont, CA.
5Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.
6Baylor College of Medicine, Houston, TX.
7Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.
8Medstar Georgetown University-Hospital-Lombardi Comprehensive Cancer Center, Washington, DC.
9University of Chicago, Chicago, IL.
10University of Pennsylvania, Philadelphia, PA.
11University of North Carolina, Chapel Hill, NC.
12University of Alabama at Birmingham, Birmingham, AL.
13Rogel Cancer Center, University of Michigan, Ann Arbor, MI.
14University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA.
15Vanderbilt University Medical Center, Nashville, TN.
16Duke University and Duke Cancer Institute, Durham, NC.
17Tidal Health, Peninsula Regional Medical Center, Salisbury, MD.
18Anne Arundel Medical Center, Annapolis, MD.
19Inova Schar Cancer, Fairfax, VA.
Abstract
PURPOSE: Patients with stage II/III human epidermal growth factor receptor 2 (HER2)-positive or triple-negative breast cancer (TNBC) frequently receive neoadjuvant therapy (NAT). Although pathologic complete response (pCR) correlates with improved outcomes, many non-pCR patients have long-term survival. Circulating tumor-DNA (ctDNA) minimal residual disease (MRD) assessment may provide additional…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans